In the United States alone, about 1 in 10 adults use these drugs regularly. Some well-known brands include Prilosec, Nexium, ...

Ardelyx's IBSRELA shows strong 57% sales growth, but faces stiff competition and uncertain sustainability. Click here to read ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the. On June 4, the company published pre-specified analyses for its ...

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

If you take OTC proton pump inhibitors (PPIs), you could be among the uncounted. Familiar brands include Prilosec (omeprazole ...

Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

Unicycive, which was seeking approval of oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, said the FDA issued a so-called complete response letter ...

Unicycive Therapeutics Inc (NASDAQ:UNCY) saw its shares plunge 26% in early trading after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the company’s ...

Unicycive Therapeutics (UNCY) announced that the U.S. Food and Drug Administration has issued a CRL for its New Drug Application for OLC to treat ...

Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing ...